SEC Tracker
Get the app

Bio-Rad Laboratories BIO

Bio-Rad Laboratories Q1 FY24: revenue $610.8M; diluted EPS $13.45

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Bio-Rad Laboratories reported for Q1 FY24, the quarter ended Mar 31, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$610.8MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income$383.9MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Diluted EPS$13.45No year-earlier figure tagged10-Q income statement, on EDGAR
  4. Cash and cash equivalents$433.3MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  5. Cash from operations$69.8MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Bio-Rad Laboratories files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3826 and related industry codes: the same peer list as the financial tables.

  1. Ralliant RAL public float $3.0B, Feb 23, 2026
  2. Itron ITRI public float $5.9B, Jun 30, 2025
  3. Revvity RVTY public float $11.3B, Jun 28, 2025
  4. Vontier VNT public float $5.4B, Jun 27, 2025
  5. Bruker BRKR public float $4.3B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.